EV68-228-N
- Generic Name
- EV68-228-N
Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults
Phase 1
Completed
- Conditions
- Enterovirus Infection
- Interventions
- Other: Placebo for EV68-228-N
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-05-02
- Target Recruit Count
- 36
- Registration Number
- NCT06444048
- Locations
- 🇺🇸
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath